Draft:Danesh Alam

Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page.

Draft:Danesh Alam

Dr. Danesh Alam Psych/MD

Dr. Alam was born Danesh Afaq Alam. He is an American Citizen that was born 1968 in Hyderabad, India. He is an Internationally renowned Psychiatrist[1], Medical Reviewer, Physician and Addictionologist. He has been Principal Investigator for 43 mental health medications presently on the market today and Sub-Investigator for another 24. He holds Academic affiliations to Northwestern University and University of Illinois, Chicago where he completed his residency. His continued work and research contribute to the changing of lives for those struggling with mental and behavioral health conditions, dementia and substance use disorders. He is Assistant Professor of Clinical Psychiatry, Northwestern University, Feinberg School of Medicine[2] (2016 - current), Principal Investigator, Neuroscience Research Institute[3] (2002 – current) and Patient Advocate and Consultant, Ambrosia Behavioral Health (2021-current).

Education and Training

Fellowship:
University of Illinois at Chicago, School of Medicine
Residency:
LinkedIn
Danesh Alam | LinkedIn

YouTube

https://www.youtube.com/watch?v=ezyXAyEs13g

https://www.youtube.com/watch?v=0lP0pkiHsyM

Medical School:
Rajiv Gandhi Institute of Medical Sciences, M.B.B.S., 1994

Licensure:

Board Certification:                                                

Addiction Certification:

  • American Board of Preventive Medicine, Addiction Medicine 2017
  • Diplomate American Board of Addiction Medicine, 2004, recertified November 2014

Honors and Awards:

  • Presidential Award, Illinois Psychiatric Society, 2019[5]
  • Distinguished Fellow, American Society of Addiction Medicine 2018[6]
  • Distinguished Fellow, American Psychiatric Association, 2013[7]
  • Fellow, American Psychiatric Association, 2009
  • Fellow, American Society of Addiction Medicine, 2015
  • Eleanor B. Pillsbury Fellow Award for Research (July 2001-June 2002)
  • National Institute of Mental Health and American Association of Clinical Psychopharmacology Fellowship Award (April 2002)
  • Pfizer Career Directions Award: Outstanding PGY III Resident- (May 2000)

Professional Societies:

  • President, Illinois Psychiatric Society 2017-2018[8]
  • President, Illinois Society of Addiction Medicine 2014 – 2016
  • Director at Large, Illinois Society of Addiction Medicine 2009-2020
  • Continuing Medical Education Committee, Florida Psychiatric Society 2023-current
  • Government Affairs Committee, Illinois Psychiatric Society, 2012- current
  • Council, Illinois Psychiatric Society, 2012- current
  • Council on Medical Care, Illinois State Medical Society, 2018-2020
  • Member, American Medical Association[9]
  • Member, Scientific Committee, Florida Psychiatric Society 2023-current

Past Positions

  • Medical Director and Vice Chair, Northwestern Medicine Central Dupage Hospital 2009-2024
  • Co-Founder, Just Believe Recovery Pennsylvania/Carbondale 2014 - 2019
  • Consulting Psychiatrist, Montenido Eating Disorders Program, Winfield, Illinois 2020-2022
  • Clinical Instructor- Visiting, Department of Psychiatry, Rush University Medical Center 2003-2020
  • Founding Medical Director, Sunspire Heartland, (Residential Substance Abuse program) 2015-2018
  • Medical Director, Day Hospital programs, Alexian Brothers Center for Addiction     Medicine and Research Psychiatrist, Alexian Center for Psychiatric Research (both an Alexian Brothers Behavioral Health Hospital) (2008-2009)
  • Associate Psychiatrist, Geriatric Care Associates, Westmont, Illinois.2002-current (2002-2015)
  • Consultant, Professional’s program for chemical dependency, Resurrection Behavioral Health (formerly-Rush Behavioral Health) Oak Park, Illinois. A nationally recognized treatment center for healthcare professionals. (2002-2008)
  • Medical Director- Research, Linden Oaks Hospital at Edward, Naperville, Illinois (2002-2004)
  • Consultant, emergency room (ER) at St Bernard Hospital (2001-2002)
  • Consultant, ER at Jackson Park Hospital (2000-2002)
  • Research Assistant, Immunogenetics Inc., Buena, NJ (1996-1997)
  • Advisor, Depression and Bipolar Support Alliance ( DBSA) (2009-2016)

Research (Selected Studies):

Principal Investigator:
  • Principal Investigator: A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled,    Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults with Major Depressive Disorder (MDD), with or without Anxious Distress.
  • Principal Investigator: A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Major Depressive Disorder.
  • Principal Investigator: A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of BHV-7000 Monotherapy inMajor Depressive Disorder.
  • Principal Investigator: A Randomized, Double-blind, Multi-center, Placebo-controlled study Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia.
  • Principal Investigator: A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open-label Long-term Extension Treatment with Aticaprant.
  • Principal Investigator: A Phase 2, Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of BHV-7000 in Treatment of Bipolar I Disorder.
  • Principal Investigator: A Phase 2/3, Multicenter, Inpatient, Placebo-Controlled, Double-blind Trial of BHV-7000 for the Acute Treatment of Manic Episodes, with or without Mixed Features, associated with Bipolar I Disorder.
  • Principal Investigator: A 52- Week, Open- Label Extension Study of ACP-204 in Adults with Alzheimer’s Disease Psychosis.
  • Principal Investigator: A Master Protocol for Three, Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled, Efficacy and Safety Studies of ACP-204 in Adults with Alzheimer’s Disease Psychosis.
  • Principal Investigator: A Randomized, Double-Blind Study Comparing 2 Maintenance Dosing Regimens of Buprenorphine Extended- Release Subcutaneous Injection (RBP- 6000) in Treatment Seeking Adult Participants with Opioid Use Disorder and High-risk Opioid Use.
  • Principal Investigator: An Open -label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De nova Subjects With DSM-5 Schizophrenia.
  • Principal Investigator: A Randomized, Double-blind, Multicenter, placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786 (deudextromethorphan hydrobrominde[d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of Alzheimer's type.
  • Principal Investigator: A Phase 3, Multicenter, Open-label, Long-term Trial Evaluating the Long-term Safety and Tolerability if Once Daily Centanafadine Capsules in Children and Adolescents with Attention-deficit/ Hyperactivity Disorder.
  • Principal Investigator: A Randomized, Double-blind, placebo-controlled Multicenter Study to Assess the efficacy and safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder.
  • Principal Investigator: An Open-label, Multicenter Trail to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder.
  • Principal Investigator: RECOVER: A Prospective, Multi-center, Randomized Controlled Blinded Trail Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment- Resistant Depression.
  • Principal Investigator: A Multicenter, Randomized, Flexible-dose, Double-blind Trial Brexpiprazole Versus Placebo for Treatment of Adults With Borderline Personality Disorder.
  • Principal Investigator: A Double-blind, Randomized, Placebo-controlled Study to evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide.
  • Principal Investigator: RECOVER: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (TRD) 2020-
  • Principal Investigator: A Multicenter, Randomized, Flexible-dose, Double-blind Trial of Brexpiprazole Versus Placebo for the Treatment of Adults with Borderline Personality Disorder 2020-
  • Principal Investigator: A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness 2020
  • Principal Investigator: A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder (MDD), Including Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for Suicide. 2020
  • Principal Investigator: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder (MDD), Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide 2016- 2019
  • Principal Investigator: A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder (MDD) 2017-2019
  • Principal Investigator: A Phase III, Multicenter Randomized double blind, placebo- controlled, parallel-group, efficacy, and safety study of Gantenerumab in patients with early (prodromal to mild) Alzheimer’s Disease. 2017-current
  • Principal Investigator: A Multicenter, Randomized, Double-blind Trial of Brexpiprazole versus Placebo for the Acute Treatment of Manic Episodes, With or Without Mixed Features, Associated with Bipolar Disorder (BPD) 2017-2019
  • Principal Investigator: A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects with Bipolar I Disorder. 2017-2019
  • Principal Investigator: A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter   Clinical Trial evaluating the efficacy, safety, and tolerability of Carpirazine in a Dose-reduction paradigm in the prevention of relapse in Bipolar I Disorder patients whose current episode is Manic or Depressive, with or without mixed Features 2018-
  • Principal Investigator: A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis 2017-2019
  • Principal Investigator:   A Double-blind, Placebo-controlled study of Cariprazine as an adjunct to antidepressants in the treatment of Patients with Major Depressive Disorder who have inadequate response to Antidepressants alone. 2018-
  • Principal Investigator: An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults with Attention-Deficit/ Hyperactivity Disorder 2018-
  • Principal Investigator: ALK6428-A302: A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Transitioning from Buprenorphine Maintenance Prior to First Dose of VIVITROL, Alkermes 2016-2017
  • Principal Investigator: ALK6428-A301: A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Prior to First Dose of VIVITROL, Alkermes 2016-2017
  • Principal Investigator: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in Patients with Bipolar I Depression, RGH-MD-54, Allergan 2016-2017  
  • Principal Investigator: An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients   With Major Depressive Disorder 2016-2017
  • Principal Investigator: A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients with Major Depressive Disorder, VLZ-MD-22, Allergan 2015-2017
  • Principal Investigator: National Institute of Drug Abuse and VA Cooperative Studies Program, Vigabatrin for Treatment for Cocaine Dependence: A phase II Study (CPP-01005) 2012-2015
  • Principal Investigator: A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 (Vyvanse) Compared with OROS-MPH (Concerta) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with ADHD. Shire (SPD489-405)2013-2015
  • Principal Investigator: A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Bipolar I Disorder. Otsuka 31-08-252 2013-2017
  • Principal Investigator: A Randomized, Double-blind, Placebo-controlled, Parallel, 26-week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy. EnVivo (EVP-6124-016) 2013-2015
  • Principal Investigator: A Multicenter 26-week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy. EnVivo (EVP-6124-017) 2013-2015
  • Principal Investigator: A Phase 3, Randomized, Multicenter, Double-blind. Placebo-controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine in the Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-label, Variable Dose Lofexidine Treatment (Days 8-14). US World Meds (USWM-LX1-3003-1) 2012-2015
  • Principal Investigator: A Phase 3, Open Label-Efficacy, Safety, and Dose-Response Study of Lofexidine in the Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-label,Variable Dose Lofexidine Treatment (Days 8-14). US World Meds (USWM- LX1-3003-1 2012-2015
Sub-Investigator
  • Sub-Investigator: A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients with Treatment-Resistant Depression. H6P-MC-HDAY. Eli Lilly.
  • Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens: Transition from BUP to XR-NTX[10]
  • Sub-Investigator: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination with Psychostimulants in Children and Adolescents Aged 6-17 Years with a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD). SPD503-313. Shire
  • Sub-Investigator: A 52-week, Multicenter, Open-Label Study to Evaluate the Effectiveness of Aripiprazole Intramuscular Depot as Maintenance Treatment in Patients with Schizophrenia “ASPIRE OPEN-LABEL” (Aripiprazole Intramuscular Depot Program in Schizophrenia). 31-08-248. Otsuka.
  • Sub-Investigator: A 38-week, Multicenter, Randomized, Double-Blind, Active-controlled Study to Evaluate the Efficacy, Safety and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients with Schizophrenia “ASPIRE EU” (Aripiprazole Intramuscular Depot Program in Schizophrenia). 31-07-247. Otsuka.
  • Sub-Investigator: A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression. D1050256. Dainippon Sumitomo Pharma
  • Sub-Investigator: A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Fixed-Flexible Dose, Parallel-Group Study of Lurasidone for the Treatment of Bipolar I Depression.D1050236. Dainippon Sumitomo Pharma.
  • Sub-Investigator: A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression. D1050235. Dainippon Sumitomo Pharma.
  • Sub-Investigator: Randomized, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed dose study comparing the efficacy and safety of LuAA21004 in acute treatment of major depressive disorder in elderly patients.12541A. Lundbeck
  • Sub-Investigator: A Study of Augmentation with Ly2216684 for Patients with Major Depressive Disorder who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment. H9P-MC-LNDK. Eli Lilly
  • Sub-Investigator: Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Quetiapine-Referenced, Fixed-Dose study of LuAA39959 in the Treatment of Depression in Patients with Bipolar I or II Disorder. 12601A. Lundbeck
  • Sub-Investigator: A long-term, phase 2, Multicenter, Randomized, Open-Label, Comparative Safety Study of LY2140023 versus Atypical Antipsychotic Standard of Care of Patients with DSM IV-TR Schizophrenia. Eli Lilly.
  • Sub-Investigator:   A multi-center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase II Comparator Study of 2 Oral Dose Groups of AZD7325 and Lorazepam in Subjects with Generalized Anxiety Disorder (GAD). Astra Zeneca
  • Sub-Investigator:   A phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo- Controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects with Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants. Astra Zeneca    
  • Sub-Investigator:   A Single Blind Placebo Controlled Trial of the Safety and Efficacy of IM Aripiprazole in patients with Schizophrenia. Otsuka
  • Sub-Investigator:   A Controlled Trial of Safety and Efficacy of Zonisamide Versus Placebo in patients with Bipolar Disorder. Capitol Clinical Research Associates
  • Sub-Investigator:    A Controlled Trial of Safety and Efficacy of Zonisamide Versus Placebo in patients with Bipolar Depression. Capitol Clinical Research Associates
  • Sub-Investigator:  Repetitive Transcranial Magnetic Stimulation in Depression. Neuronetics[11]
  • Sub-Investigator:  Randomized Placebo Controlled trial evaluating the efficacy and safety of Asenapine as an adjunctive agent in the treatment of Bipolar disorder. Pfizer/Organon
  • Sub-Investigator: Growth Hormone in the Treatment of Late Onset Depression. Genetech(993-C10)-Investigator Initiated
  • Sub-Investigator: Risperidone for Psychotic Depression. Janssen Research Foundation (RIS-USA-248)-Investigator Initiated
  • Sub-Investigator: Multicenter, Randomized, Double-Blind Study of Flexible Doses of Aripiprazole versus Perphenazine in the Treatment of Patients with Treatment-Resistant Schizophrenia. Bristol-Myers Squibb Company (CN138-032)
  • Sub-Investigator: The Efficacy and Safety of Single Dosage Ranges of Risperidone versus Placebo in the Treatment of Manic Episodes Associated with Bipolar I Disorder. Janssen Research Foundation (RIS-USA-239)
  • Sub-Investigator:  Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Maintenance Treatment of Patients with Bipolar Disorder. Bristol-Myers Squibb Company (CN138-010-033)
  • Sub-Investigator:  Aripiprazole Acute Schizophrenia Inpatient Study. Bristol-Myers Squibb Company (CN138-001)

Publications/Abstract:

1.     Alam DA, Sharma RP. Cytochrome Enzyme Genotype and the Prediction of Therapeutic Response to Psychotropics. Psychiatric Annals 31:12/December 2001[12] [13]

2.     Janicak PG, Dowd SM, Martis B, Alam DA, Beedle D, Krasuski J, Strong M, Sharma RP, Rosen C, Viana M. Repetitive Transcranial Magnetic Stimulation versus Electroconvulsive Therapy for Major Depression: Preliminary Results of a Randomized Trial. Biological Psychiatry April 15, 2002;659-667

3.     D.Alam. Repetitive Transcranial Magnetic Stimulation versus Electroconvulsive Therapy for Major Depression:Preliminary Results of a Randomized Trial. Presentation at the Annual Meeting of the Society of Transcranial Magnetic Stimulation May 2002.

4.     Janicak PG, Dowd SM, Martis B, Alam DA, Beedle D, Krasuski J, Strong M, Sharma RP, Rosen C, Viana M. Repetitive Transcranial Magnetic Stimulation versus Electroconvulsive Therapy for Major Depression: Preliminary Results of a Randomized Trial. New research abstracts, Annual Meeting of the Society of Biological Psychiatry May 2002. Presenting author.(Biol Psychiatry 2002;51:1S198S)

5.     Janicak PG, Dowd SM, Martis B, Alam DA, Beedle D, Krasuski J, Strong M, Sharma RP, Rosen C, Viana M. Repetitive Transcranial Magnetic Stimulation versus Electroconvulsive Therapy for Major Depression: Preliminary Results of a Randomized Trial. New research abstracts, Annual Meeting of the Society of Transcranial Magnetic Stimulation May 2002. Presenting author.(Biol Psychiatry 2002;51:1S198S)

6.     Martis B, Alam DA, Dowd SM, Hill SK, Sharma RP, Rosen C, Pliskin N, Martin E, Carson V, Janicak PG. Neurocognitive effects of Repetitive Transcranial Magnetic Stimulation in Major Depression. Clinical Neurophysiology. 2003 Jun;114(6):1125-32.

7.     B Martis, D Alam, S Hill, SM Dowd, RP Sharma, C Rosen, EM Martin, V Carson, PG. Janicak. Cognitive Assessment of Patients with Major Depression Treated with Repetitive Transcranial Magnetic Stimulation. New Research Ab stracts. Annual Meeting of the Society of Biological Psychiatry. May 2003

8.     PG Janicak, SM Dowd, D Beedle, MJ Strong, D Alam. Repetitive Transcranial Magnetic Stimulation in adult and older patients. Abstract. 11th International Psychogeriatric Congress, Chicago,  2003

9.     D.Alam. Aripiprazole. Formulary review. American Journal of Health-System Pharmacy. 60(23):2437-2445, December 1, 2003. Editorial Review.

10.   Janicak PG, Beedle D, Dowd SM, Martis B, Alam D, Krasuski J, Strong MJ, Sharma R, Rosen C, Viana M. Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. Abstract. 14th Annual Meeting of the Association for Convulsive Therapy; 2004 May 2, New York, NY.

11.  Alam DA, Janicak PG. Schizophrenia: The Role of Psychopharmacotherapy in Improving Long Term Outcome. Directions in Psychiatry. Nov 2004.

12.  Angres D, Delisi S, Alam D, Williams BW. A Programmatic Approach to Treating Physicians with a Dual Diagnosis Psychiatric Annals. October 2004[14]

13.  Janicak PG, Dowd SM, Strong MJ, Alam D, Beedle D. Is rTMS an Alternative to ECT for Major Depression?  Psychiatric Annals.Feb.2005.

14.  Alam D, D H Angres. Advances in Pharmacotherapy of Alcoholism.  International Drug Therapy Newsletter, Vol 42, Number 3, Mar 2007 (17-26).

15.  Alam D, Martorana A. Addiction Treatment: Levels of Care Determination. Clinics in Primary Care. 2013.Book Chapter.

16.  C Gorodetzky, M Fishman, T Clinch, D Alam et al. Safety and Efficacy of Lofexidine for withdrawal management of Opioid Detoxification. Abstract, American Society of Addiction Medicine Annual Meeting April 2016

17.  Manelli P, Comer SD, Alam D et.al. The Transition from Buprenorphine Treatment to XR-NTX:A Randomized double-blind Study. Abstract, American Society of Addiction Medicine,Annual Meeting April 2018.

18.  Comer SD, Manelli P, Alam D et.al. The Transition from Buprenorphine Treatment to XR-NTX:A Randomized double-blind Study. Abstract, The College on Problems of Drug Dependence ( CPDD) June 2018

19.  Comer SD, Manelli P, Alam D et.al. Efficacy of oral naltrexone with buprenorphine for transitioning from buprenorphine to XR-NTX: A hybrid residential-outpatient randomized control trial. The College on Problems of Drug Dependence (CPDD) 9-14 June 2018, San Diego, CA.

20.  Comer SD, Manelli P, Alam D et.al. Cognitive Outcomes in Transition from Buprenorphine Maintenance to Extended-Release Naltrexone in Opioid Use Disorder. The College on Problems of Drug Dependence ( CPDD ) 9-14 June 2018, San Diego, CA.

21.  Alam D. Lofexidine for Opioid Use disorders, ASCP, Annual Meeting Miami, May 29-June 1st, 2018

22.  T Kosten, Alam D, N Nangia et. al. Cognitive Outcomes in Transition from Buprenorphine Maintenance to XR-NTX in Opioid Use Disorder. American Academy of Addiction Psychiatry, 29th Annual Meeting and Symposium. December 2018

23.  Fishman M, Tirado C, Alam D et al. Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial. J Addict. Med. 2019 May/Jun;13 (3):169-176

24.  D. Alam, C. Tirado, M Pirner, T Clinch. The efficacy of Lofexidine for mitigating opioid withdrawal symptoms: results from two randomized, placebo-controlled trials. J of Drug Assessment. Vol. 9. 2020, Issue-1.

25.  Comer SD, Manelli P, Alam D et.al. Transition of patients with Opioid Use disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens. The American Journal on Addictions, 29: 313–322, 2020

26.   American Society of Addiction Medicine (ASAM criteria), Chapter on Co-Occurring Disorders. Co-Editor 2023.Book Chapter.

Presentations:

  • Repetitive Transcranial Magnetic Stimulation versus Electroconvulsive Therapy for Major Depression:  Preliminary Results of a Randomized Trial. Presentation at the Annual Meeting of the Society of Transcranial Magnetic Stimulation May 2002.[15]
  • Reviewed the current status of “Vagal Nerve Stimulation for Major Depressive Disorder” for the Clinical Technology Assessment Committee, October, 2005. United Behavioral Health.
  • Monthly Grand Rounds Host, Substance Use Disorders, Optum Health Behavioral Solutions 2014-2020
  • ASAM ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care, Course Director, Conference sponsored by the Illinois Society of Addiction Medicine. Winter 2013 and Spring 2014.
  • Freud Meets Buddha: Mindfulness, Trauma and Process Addictions, Chicago, March 8-11,2017, Presenter- Addictive disorders[16]
  • Contingency Management in the Treatment of Addictive Disorders, Presenter- American Society of Addiction Medicine, Annual Meeting April 6-9 2017
  • Lofexidine for Opioid Use disorders, ASCP, Annual Meeting Miami, May 29-June 1st, 2018[17]

Media interviews:

  • Northwestern Medicine- 2023/24 Social Media Campaign various.
  • Featured State Physician, Illinois State Medical Society, Members Making it Work: Medication Assisted Treatment (MAT) for Opioid Use Disorder June 2018
Television:
  • Teens and COVID 19, Fox 32, April 28, 2020
  • Parents must help Children understand Covid19 crisis ABC 7 Chicago, April 28, 2020
  • Alcohol Use and COVID 19, Fox 32, Chicago, April 9, 2020
  • New Nasal spray could help combat depression, Fox 32 Chicago, Mar 13 2019 Chicago
  • FDA approves Ketamine Nasal Spray, Mar 11, 2019 WTTW, Chicago
  • NBC Live with Lester Holtz, Video Game Addiction, February 2019
  • Opioid Crisis, WTKR, live Nov 8 2019
  • Can Apple and Facebook Make Their Products Less Addictive? Chicago Tonight, WTTW Chicago, 15 Jan 2018
  • WVIA Public Television, Panelist Call the Doctor Series. September 2015 Interview- Outpatient Addiction
Radio/Publication:
  • Interview, The Financial Times, April 20, 2020, Mental Health Opinion, All the Fridges full of Booze are a Lockdown Hazard
  • Interview Chicago Tribune, Alcohol Use and COVID19, April 8, 2020
  • CBD Oil May Help Limit Cravings and Anxiety in Heroin Users, NBC news, May 21, 2019
  • Reboot Illinois, Interview on Heroin Addiction May 2015
  • WGN 720 A.M. Interview by Mike McConnell, Violence and mental illness.Jan.11,2011
  • WBBM 780 A.M. Interview by Bernie Tafoya. Bears Blues Report. February, 2011
  • WBBM 780 A.M. Interview by Felicia Middlebrook. New Year Resolutions. January 1,2010
  • WBBM 780 A.M. Interview by Felicia Middlebrook. Suicides during the holiday season. January 3rd, 2010.
  • Interview: Prescription for Disaster. Gatehouse News Service for Red Ribbon Week. September 2010
  • Chicago Hospital News, October 2009. Profiled Physician.
  • Daily Herald. Interview. Weighing the health benefits of alcohol. September 2009
  • Interview: Community Health Magazine. Blue Christmas. December 2009

References

  1. ^ "Danesh A Alam, MD | AMA Find a Doctor | Find doctors in the US by name, location, and specialty | AMA". find-doctor.ama-assn.org. Retrieved 2025-08-04.
  2. ^ "Danesh A Alam: Department of Psychiatry & Behavioral Sciences: Feinberg School of Medicine". www.psychiatry.northwestern.edu. Retrieved 2025-07-31.
  3. ^ "Mental Health Treatment Center | South Florida". Neuroscience Institute. Retrieved 2025-08-04.
  4. ^ "FL DOH MQA Search Portal | License Verification For Practitioner Details". mqa-internet.doh.state.fl.us. Retrieved 2025-08-04.
  5. ^ "About-History of IPS". Illinois Psychiatric Society. Retrieved 2026-02-11.
  6. ^ "Danesh A Alam: Department of Psychiatry & Behavioral Sciences: Feinberg School of Medicine". www.psychiatry.northwestern.edu. Retrieved 2026-02-11.
  7. ^ "Danesh A Alam: Department of Psychiatry & Behavioral Sciences: Feinberg School of Medicine". www.psychiatry.northwestern.edu. Retrieved 2026-02-11.
  8. ^ "About-History of IPS". Illinois Psychiatric Society. Retrieved 2025-08-04.
  9. ^ "Danesh A Alam, MD | AMA Find a Doctor | Find doctors in the US by name, location, and specialty | AMA". find-doctor.ama-assn.org. Retrieved 2026-02-11.
  10. ^ Comer, Sandra D.; Mannelli, Paolo; Alam, Danesh; Douaihy, Antoine; Nangia, Narinder; Akerman, Sarah C.; Zavod, Abigail; Silverman, Bernard L.; Sullivan, Maria A. (July 2020). "Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens". The American Journal on Addictions. 29 (4): 313–322. doi:10.1111/ajad.13024. ISSN 1521-0391. PMC 7383475. PMID 32246728.
  11. ^ Medical Advisory Secretariat (2004). "Repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an evidence-based analysis". Ontario Health Technology Assessment Series. 4 (7): 1–98. ISSN 1915-7398. PMC 3387754. PMID 23074457.
  12. ^ "HistCite - The sequence of the human genome (Venter)". garfield.library.upenn.edu. Retrieved 2025-08-04.
  13. ^ "HistCite - Record 562: Cytochrome enzyme genotype and the prediction of therapeutic response to psychotropics". garfield.library.upenn.edu. Retrieved 2025-08-04.
  14. ^ Angres, Daniel; Delisi, Stephen; Alan, Danesh; Williams, Betsy White (October 2004). "A Programmatic Approach to Treating Physicians With A Dual Diagnosis". Psychiatric Annals. 34 (10): 776–780. doi:10.3928/0048-5713-20041001-17.
  15. ^ Alam, Densh (April 2002). "Comment on "repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial"".
  16. ^ "Speakers: 2017 Chicago - Freud Meets Buddha: Mindfulness, Trauma and Process Addictions". vendome.swoogo.com. Retrieved 2025-09-03.
  17. ^ Fishman, Marc; Tirado, Carlos; Alam, Danesh; Gullo, Kristen; Clinch, Thomas; Gorodetzky, Charles W. (May 2019). "Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial". Journal of Addiction Medicine. 13 (3): 169–176. doi:10.1097/ADM.0000000000000474. ISSN 1932-0620. PMID 30531234.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.